Source: Medthority

Antares Pharma: Halozyme Therapeutics acquires Antares Pharma

Halozyme Therapeutics, Inc.and Antares Pharma, Inc. have announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash.

Read full article »
Antares Pharma's Competitors | Antares Pharma's News | Antares Pharma's Financials
Stay up-to-date with the latest news on Antares Pharma
Est. Annual Revenue
$100-500M
Est. Employees
100-250
Robert F Apple's photo - President & CEO of Antares Pharma

President & CEO

Robert F Apple

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Antares Pharma